Press Releases
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
GT Biopharma to Present at The Virtual 33rd Annual Roth Conference
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
